Literature DB >> 11528470

Identification of an angiogenic mitogen selective for endocrine gland endothelium.

J LeCouter1, J Kowalski, J Foster, P Hass, Z Zhang, L Dillard-Telm, G Frantz, L Rangell, L DeGuzman, G A Keller, F Peale, A Gurney, K J Hillan, N Ferrara.   

Abstract

The known endothelial mitogens stimulate growth of vascular endothelial cells without regard to their tissue of origin. Here we report a growth factor that is expressed largely in one type of tissue and acts selectively on one type of endothelium. This molecule, called endocrine-gland-derived vascular endothelial growth factor (EG-VEGF), induced proliferation, migration and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. However, EG-VEGF had little or no effect on a variety of other endothelial and non-endothelial cell types tested. Similar to VEGF, EG-VEGF possesses a HIF-1 binding site, and its expression is induced by hypoxia. Both EG-VEGF and VEGF resulted in extensive angiogenesis and cyst formation when delivered in the ovary. However, unlike VEGF, EG-VEGF failed to promote angiogenesis in the cornea or skeletal muscle. Expression of human EG-VEGF messenger RNA is restricted to the steroidogenic glands, ovary, testis, adrenal and placenta and is often complementary to the expression of VEGF, suggesting that these molecules function in a coordinated manner. EG-VEGF is an example of a class of highly specific mitogens that act to regulate proliferation and differentiation of the vascular endothelium in a tissue-specific manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528470     DOI: 10.1038/35091000

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  127 in total

Review 1.  New insights into endothelial diversity.

Authors:  James E Tomlinson; James N Topper
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

2.  Nociceptive sensitization by the secretory protein Bv8.

Authors:  Lucia Negri; Roberta Lattanzi; Elisa Giannini; Alessio Metere; Mariantonella Colucci; Donatella Barra; Günther Kreil; Pietro Melchiorri
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Vascularization of rat pituitary autografts.

Authors:  Matilde Lombardero; Andres Quintanar-Stephano; Sergio Vidal; Eva Horvath; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  J Anat       Date:  2006-05       Impact factor: 2.610

Review 4.  Emerging concept in angiogenesis: specification of arterial and venous endothelial cells.

Authors:  Thomas N Sato
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

Review 5.  Angiogenesis and marrow stromal cell fates: roles in bone strength.

Authors:  Dwight A Towler
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 6.  The role of prokineticins in the pathogenesis of hypogonadotropic hypogonadism.

Authors:  Ana Paula Abreu; Ursula B Kaiser; Ana Claudia Latronico
Journal:  Neuroendocrinology       Date:  2010-05-21       Impact factor: 4.914

7.  Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.

Authors:  Milena De Felice; Pietro Melchiorri; Michael H Ossipov; Todd W Vanderah; Frank Porreca; Lucia Negri
Journal:  Neurosci Lett       Date:  2012-05-26       Impact factor: 3.046

8.  Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain.

Authors:  Orit Jacobson; Ido D Weiss; Gang Niu; Gianfranco Balboni; Cenzo Congiu; Valentina Onnis; Dale O Kiesewetter; Roberta Lattanzi; Severo Salvadori; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

9.  Chronic systemic hypoxia causes intra-retinal angiogenesis.

Authors:  Alex J Shortt; Katherine Howell; Colm O'Brien; Paul McLoughlin
Journal:  J Anat       Date:  2004-11       Impact factor: 2.610

Review 10.  Angiogenesis and hypoxia in the kidney.

Authors:  Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2013-03-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.